CIK: 0001907884
Total reported value
$1.6B
Reporting period: 2026-03-31 · Number of holdings: 39
Kynam Capital Management, LP disclosed 39 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.6B and a quarterly turnover rate of 40.0%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "K"
Kynam Capital Management, LP's disclosed holdings carry a Herfindahl concentration index of 0.067 — mathematically equivalent to about 15 equally-sized positions, well below its 39 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.23), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 1% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim COGT
-34.5% -$63.6M
Add TVTX
+368.0% $52.2M
Trim VERA
-1.0% -$37.1M
Trim WVE
-55.5% -$29.9M
Add CTMX
+67.4% $32.4M
Add PCVX
0.0% $35.0M
Showing top 37 holdings (of 39 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 11.60% | +0.79% | — | |
| 2 | CLDX | Celldex Therapeutics INC | Stock-Other | 11.43% | +1.12% | -1.73% | |
| 3 | PCVX | Vaxcyte INC | Stock-Other | 10.48% | +1.87% | — | |
| 4 | COGT | Cogent Biosciences INC | Stock-Other | 9.59% | -4.40% | -34.51% | |
| 5 | VERA | Vera Therapeutics INC | Stock-Other | 8.43% | -2.68% | -1.01% | |
| 6 | BEAM | Beam Therapeutics INC | Stock-Other | 5.41% | -0.57% | +9.03% | |
| 7 | TVTX | Travere Therapeutics INC | Stock-Other | 4.44% | +3.18% | +368.04% | |
| 8 | CTMX | Cytomx Therapeutics INC | Stock-Other | 4.35% | +1.91% | +67.44% | |
| 9 | BCRX | Biocryst Pharmaceuticals INC | Stock-Other | 3.34% | -1.33% | -39.35% | |
| 10 | VRDN | Viridian Therapeutics INC | Stock-Other | 2.83% | -0.09% | +59.24% | |
| 11 | CGEM | Cullinan Therapeutics INC | Stock-Other | 2.73% | +0.67% | — | |
| 12 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.49% | +2.49% | NEW | |
| 13 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 2.26% | +0.39% | +0.55% | |
| 14 | APLSUSD | Apellis Pharmaceuticals INC | Stock-Other | 2.05% | +0.59% | -9.20% | |
| 15 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.76% | +1.76% | NEW | |
| 16 | MBX | Mbx Biosciences INC | Stock-Other | 1.72% | -0.16% | — | |
| 17 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.65% | -0.25% | +3.32% | |
| 18 | STRO | Sutro Biopharma INC | Stock-Other | 1.34% | +0.99% | +81.94% | |
| 19 | RVMD | Revolution Medicines INC | Stock-Healthcare | 1.24% | +1.24% | NEW | |
| 20 | BNR | Burning Rock Biotech Ltd-adr | Stock-Other | 1.22% | -0.06% | +23.39% | |
| 21 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 1.16% | +1.16% | NEW | |
| 22 | NRIX | Nurix Therapeutics INC | Stock-Other | 1.14% | -1.25% | -39.36% | |
| 23 | PHVS | Pharvaris N.V. | Stock-Other | 1.12% | -0.02% | — | |
| 24 | EVMN | Evommune INC | Stock-Other | 0.89% | +0.69% | +237.23% | |
| 25 | RLAY | Relay Therapeutics INC | Stock-Other | 0.87% | +0.10% | — | |
| 26 | GERN | Geron CORP | Stock-Other | 0.63% | +0.34% | +97.79% | |
| 27 | ✓ | Engene Holdings INC | Stock-Other | 0.57% | -0.29% | -9.11% | |
| 28 | DSGN | Design Therapeutics INC | Stock-Other | 0.51% | +0.05% | — | |
| 29 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.43% | -1.93% | -55.50% | |
| 30 | CLYM | Climb Bio INC | Stock-Other | 0.42% | +0.16% | -2.43% | |
| 31 | AMRN | Amarin CORP PLC -adr | Stock-Other | 0.42% | +0.07% | +21.35% | |
| 32 | BHVN | Biohaven Ltd. | Stock-Other | 0.37% | -0.14% | — | |
| 33 | PRLD | Prelude Therapeutics INC | Stock-Other | 0.34% | +0.19% | +101.88% | |
| 34 | CRBU | Caribou Biosciences INC | Stock-Other | 0.29% | +0.04% | — | |
| 35 | ALEC | Alector INC | Stock-Other | 0.27% | +0.07% | — | |
| 36 | ✓ | Proqr Thrapeutics N V | Stock-Other | 0.16% | -0.04% | — | |
| 37 | CADL | Candel Therapeutics INC | Stock-Other | 0.06% | +0.06% | NEW |
Performance for Q3 2026
+6%
Performance Last 4 Quarters
+98.3%
Based on 85% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 39 | $1.6B | 40 | |
| 2025-12-31 | 37 | $1.6B | 40 | |
| 2025-09-30 | 35 | $1.3B | 63 | |
| 2025-06-30 | 31 | $928.8M | 0 | |
| 2025-03-31 | 32 | $1.2B | 0 | |
| 2024-12-31 | 30 | $1.7B | 0 | |
| 2024-09-30 | 25 | $1.3B | 0 | |
| 2024-06-30 | 26 | $1.3B | 0 | |
| 2024-03-31 | 23 | $955.5M | 0 | |
| 2023-12-31 | 24 | $902.6M | 0 | |
| 2023-09-30 | 30 | $611.4M | 0 | |
| 2023-06-30 | 26 | $727.1M | 0 | |
| 2023-03-31 | 35 | $774.6M | 0 | |
| 2022-12-31 | 31 | $651.9M | 0 | |
| 2022-09-30 | 37 | $474.6M | 0 | |
| 2022-06-30 | 34 | $391.6M | 0 | |
| 2022-03-31 | 33 | $308.3M | 0 | |
| 2021-12-31 | 32 | $187.1M | 0 |
Kynam Capital Management, LP's most significant position changes for 2026-03-31: Sold out: Tyra Biosciences INC (TYRA); New buy: UroGen Pharma Ltd. (URGN); Sold out: Cg Oncology INC (CGON); New buy: Legend Biotech Corp-adr (LEGN); Sold out: Dynavax Technologies CORP (DVAX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TVTX | Travere Therapeutics INC | +3.2% | +368.04% | Add |
| 2 | CTMX | Cytomx Therapeutics INC | +1.9% | +67.44% | Add |
| 3 | PCVX | Vaxcyte INC | +1.9% | — | Unchanged |
| 4 | CLDX | Celldex Therapeutics INC | +1.1% | -1.73% | Trim |
| 5 | STRO | Sutro Biopharma INC | +1% | +81.94% | Add |
| 6 | SNDX | Syndax Pharmaceuticals INC | +0.8% | — | Unchanged |
| 7 | EVMN | Evommune INC | +0.7% | +237.23% | Add |
| 8 | CGEM | Cullinan Therapeutics INC | +0.7% | — | Unchanged |
| 9 | APLSUSD | Apellis Pharmaceuticals INC | +0.6% | -9.20% | Trim |
| 10 | 4XC1 | Kalvista Pharmaceuticals INC | +0.4% | +0.55% | Add |
| 11 | GERN | Geron CORP | +0.3% | +97.79% | Add |
| 12 | PRLD | Prelude Therapeutics INC | +0.2% | +101.88% | Add |
| 13 | CLYM | Climb Bio INC | +0.2% | -2.43% | Trim |
| 14 | RLAY | Relay Therapeutics INC | +0.1% | — | Unchanged |
| 15 | AMRN | Amarin CORP PLC -adr | +0.1% | +21.35% | Add |
| 16 | ALEC | Alector INC | +0.1% | — | Unchanged |
| 17 | DSGN | Design Therapeutics INC | +0.1% | — | Unchanged |
| 18 | CRBU | Caribou Biosciences INC | 0% | — | Unchanged |
| 19 | PHVS | Pharvaris N.V. | 0% | — | Unchanged |
| 20 | ✓ | Proqr Thrapeutics N V | 0% | — | Unchanged |
| 21 | BNR | Burning Rock Biotech Ltd-adr | -0.1% | +23.39% | Add |
| 22 | VRDN | Viridian Therapeutics INC | -0.1% | +59.24% | Add |
| 23 | BHVN | Biohaven Ltd. | -0.1% | — | Unchanged |
| 24 | MBX | Mbx Biosciences INC | -0.2% | — | Unchanged |
| 25 | IMCR | Immunocore Holdings Plc-adr | -0.3% | +3.32% | Add |
| 26 | ✓ | Engene Holdings INC | -0.3% | -9.11% | Trim |
| 27 | BEAM | Beam Therapeutics INC | -0.6% | +9.03% | Add |
| 28 | NRIX | Nurix Therapeutics INC | -1.3% | -39.36% | Trim |
| 29 | BCRX | Biocryst Pharmaceuticals INC | -1.3% | -39.35% | Trim |
| 30 | WVE | Wave Life Sciences Ltd. | -1.9% | -55.50% | Trim |
| 31 | VERA | Vera Therapeutics INC | -2.7% | -1.01% | Trim |
| 32 | COGT | Cogent Biosciences INC | -4.4% | -34.51% | Trim |
| 33 | TYRA | Tyra Biosciences INC | — | EXIT | Sold out |
| 34 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 35 | CGON | Cg Oncology INC | — | EXIT | Sold out |
| 36 | LEGN | Legend Biotech Corp-adr | — | NEW | New buy |
| 37 | DVAX | Dynavax Technologies CORP | — | EXIT | Sold out |
| 38 | RVMD | Revolution Medicines INC | — | NEW | New buy |
| 39 | SLNOEUR | Soleno Therapeutics INC | — | NEW | New buy |
| 40 | OMER | Omeros CORP | — | EXIT | Sold out |
| 41 | CADL | Candel Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-13 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001939208
Total reported value
$1.6B
85 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001133653
Total reported value
$1.6B
263 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001470766
Total reported value
$1.6B
26 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0002052213
Total reported value
$352.2M
34 stks
2026-03-31
3 of the top 5 holdings overlap, including Cogent Biosciences INC
CIK 0001397144
Total reported value
$306.9M
19 stks
2022-12-31
Stale — no recent filing
2 of the top 5 holdings overlap, including Vaxcyte INC
CIK 0001000097
Total reported value
$911.0M
67 stks
2026-03-31
1 of the top 5 holdings overlap, including Syndax Pharmaceuticals INC